Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 01 - 04 tags : Treatment save search
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
Published: 2021-01-04 (Crawled : 17:00) - biospace.com/
AMPE | $0.62 0.0% 53K
|
Health Technology
|
| O: 0.63%
H: 2.5%
C: -7.5%
covid trial treatment covid-19
HAWKINS ANNOUNCES IT HAS EXTENDED ITS WATER TREATMENT FOOTPRINT WITH ACQUISITIONS IN LOUISIANA
Published: 2021-01-04 (Crawled : 15:00) - globenewswire.com
HWKN 4 | $76.15 -1.22% -1.23% 130K
|
Distribution Services
|
| O: 1.13%
H: 0.49%
C: -1.89%
acquisition acquisitions treatment
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.26 -0.52% 0.04% 12M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.26 -0.52% 0.04% 12M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
Published: 2021-01-04 (Crawled : 13:03) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 7.21%
H: 1.76%
C: -4.52%
treatment phase 2 phase 2/3
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
Published: 2021-01-04 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell treatment
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
Published: 2021-01-04 (Crawled : 12:03) - globenewswire.com
PASG | $1.25 1.63% 1.6% 67K
|
Health Technology
|
| O: 2.35%
H: 11.2%
C: 7.45%
gene therapy fda clearance fda therapy treatment gene therapies application clearance
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
Published: 2021-01-04 (Crawled : 11:03) - globenewswire.com
INZY | $4.855 3.08% 2.99% 700K
|
Health Technology
|
| O: 4.26%
H: 11.85%
C: 8.6%
trial phase 3 phase 1 phase 2 treatment authorized
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.